Tesamorelin: the approved GHRH analog most researchers overlook
A full FDA approval, phase 3 visceral-fat data, and lessons for evaluating its gray-market cousins.
ScienceTesamorelin
Also known as: Egrifta
ClassGHRH analog
Research statusFDA-approved (branded form)
Independent tests0
Studies indexed1
Overview
Tesamorelin is an FDA-approved growth-hormone-releasing hormone analog (Egrifta) indicated for excess abdominal fat in HIV-associated lipodystrophy. Its approval pathway gives it one of the stronger evidence bases among GH-axis peptides, and phase 3 data showed selective visceral adipose reduction.
Research & Studies
Studies library-
Tesamorelin for visceral adiposity in HIV-associated lipodystrophy
Pivotal trial demonstrating selective visceral-fat reduction; basis of FDA approval.
Latest Coverage
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements